Inotiv Inc. PT receives Investment Bank Analyst Rating Update
Inotiv, Inc. (NOTV) reported Q3 EPS of ($0.15), $0.13 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $172.66 million versus the consensus estimate...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Financials, Oil & Gas and Technology sectors led shares higher. At the close in NYSE, the Dow...
Bioanalytical Systems, Inc (NASDAQ:BASI) recently introduced the ‘Embrace Automation grant program’ featuring ‘BASi Culex NxT Automated Blood Sampling System...
Inotiv, Inc. is an international contract research company that is focused on providing drug discovery and development services and analytical instruments. The Company focuses on providing drug developers with scientific research and analytical instrumentation. The Company operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.
|Average||57.00 (+222.40% Upside)|
|No. of Analysts||2|